Co-Diagnostics amends equity plan for 2026 shareholder vote
Co-Diagnostics approved an amendment to its 2025 Equity Incentive Plan to increase the number of available shares, contingent on approval at the company's 2026 special meeting.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed